| __timestamp | Bristol-Myers Squibb Company | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 15746000 |
| Thursday, January 1, 2015 | 5001000000 | 13392000 |
| Friday, January 1, 2016 | 5002000000 | 9290000 |
| Sunday, January 1, 2017 | 4849000000 | 7672000 |
| Monday, January 1, 2018 | 4551000000 | 15293000 |
| Tuesday, January 1, 2019 | 4871000000 | 22648000 |
| Wednesday, January 1, 2020 | 7661000000 | 21864000 |
| Friday, January 1, 2021 | 7690000000 | 37318000 |
| Saturday, January 1, 2022 | 7814000000 | 48130000 |
| Sunday, January 1, 2023 | 7772000000 | 108146000 |
| Monday, January 1, 2024 | 8414000000 |
Data in motion
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Bristol-Myers Squibb Company and Madrigal Pharmaceuticals, Inc. have showcased contrasting SG&A spending patterns. Bristol-Myers Squibb, a giant in the industry, has consistently allocated substantial resources, with a peak in 2022, where SG&A expenses reached approximately 7.8 billion dollars. This represents a 40% increase from 2014. In contrast, Madrigal Pharmaceuticals, a smaller player, has shown a more modest yet significant growth in SG&A spending, with a remarkable 587% increase from 2014 to 2023. This surge reflects Madrigal's aggressive expansion strategy. The data highlights the diverse approaches these companies take in managing their operational costs, offering insights into their strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?